 -- Treated first patients in Phase 2 dose-ranging trial for EDP1815 in psoriasis --- Six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast cancer expected over next 3-9 months ---Advancing newly discovered microbial extracellular vesicles as next-generation SINTAX-based medicines--- Data from Phase 1b trial evaluating EDP1815 in psoriasis spotlighted today at EADV Virtual Congress -- -- Management to host conference call at 8:30 a.m. ET -- CAMBRIDGE, Mass., Oct. 29, 2020 GLOBE NEWSWIRE -- Evelo Biosciences, Inc. Nasdaq:EVLO, a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today reported financial results and business highlights for the third quarter of 2020. 